Acazicolcept (ALPN-101)

A First-in-Class, Dual CD28/ICOS Costimulation Antagonist for Autoimmune Diseases

Acazicolcept is a first-in-class dual inhibitor of the CD28 and ICOS T cell costimulatory pathways. The molecule is being developed for treatment of severe inflammatory diseases.

Acazicolcept is a first-in-class, dual inhibitor of the CD28 and ICOS T-cell costimulatory pathways being developed for treatment of systemic lupus erythematosus (SLE). By simultaneously blocking two key costimulatory pathways, acazicolcept has the potential to improve outcomes in patients suffering from severe autoimmune/inflammatory diseases. Preclinical studies have demonstrated efficacy in models of SLE, Sjögren’s syndrome, arthritis, inflammatory bowel disease, multiple sclerosis, type 1 diabetes, uveitis, and graft versus host disease.

Synergy (NCT04835441) is a global, randomized, double-blind, placebo-controlled phase 2 clinical study of acazicolcept in moderate-to-severe SLE that initiated enrollment in June 2021.

In December 2023, we announced an amendment to the previously announced 2020 option and license agreement with AbbVie for acazicolcept.

 

For full details, please see here.

Acazicolcept (ALPN-101) is a Variant ICOSL IgV domain (vIgD™) fused to an "Effectorless" IgG Fc

Acazicolcept: A Variant ICOSL Domain (vIgD™) Fused to an “Effectorless” IgG Fc

Available therapeutics only block the CD28 pathway, acazicolcept (ALPN-101) is a dual inhibitor of two T cell costimulatory receptors, CD28 and ICOS.

Acazicolcept Blocks Both CD28 and ICOS Pathways

For more information on our ongoing clinical trials please refer to the clinical trials portion of our website. For additional information please refer to our corporate filings, corporate presentations, and scientific publications.

Join us in the discovery and development of next-generation immunotherapies.

Current job openingsLearn more about Alpine